Physician profile
Ross Heil
NPI 1265669709
$5,655.13
in general payments reported to CMS, 2019-2025
33 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $610 · 2021: $835 · 2022: $1,424 · 2023: $1,025 · 2024: $659 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,055.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,116.11 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $738.04 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $527.84 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $289.76 | 2019-2023 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $261.25 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $219.63 | 2022-2025 | Dupixent |
| Boston Scientific Corporation | $201.55 | 2020-2022 | |
| Pfizer INC. | $200.14 | 2019-2022 | |
| Gilead Sciences, INC. | $188.78 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $94.45 | 2019-2025 | |
| Celgene Corporation | $87.24 | 2022-2023 | Zeposia |
| Shionogi INC | $85.54 | 2019 | |
| Lilly USA, LLC | $80.22 | 2024 | Omvoh |
| Genzyme Corporation | $62.89 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $52.32 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $47.37 | 2023 | |
| Qol Medical, LLC | $44.21 | 2022 | |
| Redhill Biopharma INC. | $43.09 | 2022 | |
| Phathom Pharmaceuticals, INC. | $41.54 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $31.45 | 2020-2023 | Linzess |
| Shire North American Group INC | $29.27 | 2019 | |
| Allergan, INC. | $27.43 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $23.28 | 2023 | Clenpiq |
| Ardelyx, INC. | $22.21 | 2024 | Ibsrela |
| Micro-Tech Endoscopy USA, INC. | $19.52 | 2019-2024 | Blueboost |
| Ethicon US, LLC | $18.35 | 2022 | |
| Braintree Laboratories, INC. | $18.34 | 2021 | |
| Novo Nordisk INC | $15.30 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.87 | 2022 | |
| Eisai INC. | $14.54 | 2019 | |
| Lucid Diagnostics INC. | $13.01 | 2023 | |
| Exact Sciences Corporation | $12.86 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Heil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.